RegulationFast Track (United States), Orphan Drug (United States), Orphan Drug (European Union), Orphan Drug (Japan), Orphan Drug (Australia), Priority Review (Australia), Breakthrough Therapy (China), Priority Review (China), Breakthrough Therapy (United States)

Structure/Sequence

Boost your research with our RNA technology data.

view full example data

Sequence Code 319466156

Source: *****

Sequence Code 1190395904

Source: *****

Clinical Trials associated with Plozasiran

NCT06880770

/ RecruitingPhase 3

Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults With Severe Hypertriglyceridemia at High Risk of Acute Pancreatitis (SHASTA-5 Study)

This study will evaluate the efficacy and safety of plozasiran in approximately 288 adult participants with severe hypertriglyceridemia (SHTG) and history of at least two prior acute pancreatitis (AP) events not attributed to other etiologies, with at least one occurring within the last 12 months prior to screening. Eligible participants will be randomly assigned in a double-blind manner to either receive plozasiran 25 mg by subcutaneous (SC) injection every three months (Q3M) or matching placebo. Enrolled participants will be counseled to remain on the specified low-fat diet and background medications throughout the study. Following completion of the double-blind treatment period, or if the participant has a positively adjudicated AP event (whichever occurs first), participants will transition to the 12-month Open-Label Extension (OLE) treatment period receiving plozasiran 25 mg by SC injection Q3M.

Start Date24 Apr 2025

Sponsor / Collaborator

Arrowhead Pharmaceuticals, Inc.

NCT06822790

/ RecruitingPhase 3

A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia (SHASTA-10 Study)

This is an open-label study to be conducted in adults with hypertriglyceridemia (HTG) and severe hypertriglyceridemia (SHTG). Each participant must have completed all required visits per protocol in the parent study AROAPOC3-2003 (USA and Canada participants only; NCT# 05413135), AROAPOC3-3001(Canada and Japan participants only; NCT05089084), AROAPOC3-3003 (NCT06347003), AROAPOC3-3004 (NCT06347016) or AROAPOC3-3009 (Argentina, Italy, South Africa, and Spain; NCT06347133).
Subjects who previously met all eligibility requirements for AROAPOC3-3003 or AROAPOC3-3004 and were not permitted to proceed to randomization per the Sponsor's direction in order to prevent excessive over-enrollment may also be enrolled in this trial. The subjects must meet all other applicable eligibility criteria prior to enrollment and have an HbA1c results of <=10% within 30 days prior to Day 1.
Subjects entering this OLE from AROAPOC3-2003 must meet the following additional criteria to be considered for enrollment in addition to applicable eligibility criteria:
1. HbA1c ≤10% within 30 days prior to Day 1
2. Completed AROAPOC3-2001 prior to entry into AROAPOC3-2003 AND fulfill either (c) or (d)
3. Baseline fasting TG level of ≥500 mg/dL and prior history of acute pancreatitis at the time of enrollment into AROAPOC3-2001
4. Baseline fasting TG level of ≥1000 mg/dL at the time of enrollment into AROAPOC3-2001
All eligible participants will receive plozasiran administered subcutaneously (SC) approximately every 3 months for 24 months. Participants will be counseled to remain on the specified low-fat diet throughout the study in accordance with local standard of care.

Start Date09 Apr 2025

Sponsor / Collaborator

Arrowhead Pharmaceuticals, Inc.

NCT06347016

/ Active, not recruitingPhase 3

Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozsiran in Adults With Severe Hypertriglyceridemia

This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with severe hypertriglyceridemia (SHTG). After providing informed consent eligible participants will be randomized to receive 4 doses (once every 3 months) of plozasiran or placebo, and be evaluated for efficacy and safety. After Month 12, eligible participants will be offered an opportunity to continue in an optional open-label extension under a separate protocol.

Start Date23 Jul 2024

Sponsor / Collaborator

Arrowhead Pharmaceuticals, Inc.

100 Clinical Results associated with Plozasiran

100 Translational Medicine associated with Plozasiran

100 Patents (Medical) associated with Plozasiran

Literatures (Medical) associated with Plozasiran

01 Mar 2026·VACCINE

VSA-2-, a novel plant-derived adjuvant for SARS-CoV-2 subunit vaccine

Article

Author: Zou, Jing ; Adam, Awadalkareem ; Jones, Madison C ; Lee, Christy ; Peng, Bi-Hung ; Xie, Xuping ; Wang, Tian ; Wang, Pengfei ; Harrington, Brinley R

QS-21, a key component of several licensed vaccines is facing limited supply, dose-limiting toxicity and other drawbacks which together limit its broader usage. Development of saponin alternatives to QS-21 that retain its desirable adjuvant activity without its drawbacks is in high need. Incorporating an amide side chain into the more sustainable Momordica saponins (MS) I and II led to the recent discovery of two semisynthetic immunostimulatory adjuvants VSA-1 and VSA-2. Here, we showed that SARS-CoV-2 receptor-binding protein (RBD) adjuvanted with VSA-2 induced high titers of SARS-CoV-2 specific humoral and T helper-1 prone immune responses in mice comparable to that triggered by QS-21-RBD vaccination. Vaccination with VSA-2-RBD provided strong protection against SARS-CoV-2 and variants infection and the virus-induced lung inflammation and pathology similarly as QS-21-RBD vaccination. Overall, our results suggest that VSA-2 adjuvant can potentially complement the clinically proven saponin adjuvant QS-21 in vaccines against infectious diseases.

01 Jan 2026·JIMD reports

Course of Pregnancy in a Woman With Familial Chylomicronemia Syndrome Treated With Plozasiran, a Small Interfering RNA Against ApoC3

Article

Author: Poirier, Paul ; Muhsin, Ma'an ; Larouche, Miriam ; Grenon, Claudy ; Roy, Nathalie ; Brisson, Diane ; Gaudet, Daniel

ABSTRACT:

Persistent chylomicronemia is associated with severe hypertriglyceridemia (sHTG) and plasma triglycerides (TG) levels sustainably > 10 mmol/L (880 mg/dL) despite lipid lowering therapies. The main risk of persistent chylomicronemia is acute pancreatitis (AP). During the second and third trimester of pregnancy, TG levels significantly increase, which represents a serious risk of AP in women with preexisting chylomicronemia. New emerging therapies such as plozasiran, a GalNAc‐conjugated small interfering RNA (siRNA) against ApoC3, are developed to manage persistent chylomicronemia, but no data are currently available on their safety and efficacy during pregnancy. We report herein the case of a woman with persistent chylomicronemia randomized in the PALISADE study to receive plozasiran 25 mg quarterly, who had an unplanned pregnancy during the clinical trial. The 34‐year‐old patient received one dose of plozasiran 8 weeks before conception and the experimental treatment was ceased afterwards. The pregnancy went well, TG levels did not rise above 10 mmol/L (880 mg/dL) during the whole pregnancy, even during the last two trimesters where TG levels usually increase two‐ to four‐fold from baseline and she did not experience any AP episode. She delivered a healthy baby at 39 weeks. This case suggests that plozasiran might be safe for the mother and the fetus and could prevent incremental pregnancy‐driven TG elevation and occurrence of AP in women with sHTG. This is consistent with the long duration of action and hepatic half‐life of plozasiran in clinical studies where TG levels remained sustainably lower than baseline > 9 months after the last injection.

01 Dec 2025·Current Atherosclerosis Reports

Novel Therapeutics for Familial Chylomicronemia Syndrome

Review

Author: Izar, Maria Cristina ; Fonseca, Francisco Antonio Helfenstein

PURPOSE OF REVIEW:

This review discusses new treatment approaches for familial chylomicronemia syndrome (FCS), a rare disorder affecting triglyceride metabolism. The focus is on antisense oligonucleotides (ASO) and small-interfering RNA (siRNA) therapies targeting APOC3 and angiopoietin-like protein 3 (ANGPTL3).

RECENT FINDINGS:

Volanesorsen, an ASO targeting APOC3, has shown effectiveness in managing FCS, multifactorial chylomicronemia, and familial partial lipodystrophy, but its use is limited by thrombocytopenia. Emerging therapies, Olezarsen (ASO anti-APOC3) and Plozasiran (siRNA anti-APOC3), both conjugated with GalNAc, show promise in reducing acute pancreatitis risk without platelet concerns. ANGPTL3 inhibition requires residual lipoprotein lipase (LPL) activity, with only siRNA-based therapies-zodasiran and solbinsiran-under investigation. Suppressing APOC3 expression and targeting ANGPTL3 via siRNA offer significant potential, but long-term studies are needed to confirm their efficacy and safety. Future research may explore gene-editing strategies using lipid nanoparticle-based CRISPR-Cas9 delivery for more durable treatment outcomes.

106

News (Medical) associated with Plozasiran

18 Feb 2026

·www.biospace.com

Ionis Paves Its Own Path as Initial Tryngolza Launch Defies Expectations

iStock, shinpanu thamvisead Long an R&D company that partnered off assets, RNAi biotech Ionis Pharmaceuticals shifted in 2025 to bring two medicines to market alone. Analysts are already impressed—and there’s more to come in 2026. Investors were not exactly expecting Ionis’ GSK-partnered antisense oligonucleotide to achieve a functional cure in chronic hepatitis B. CEO Brett Monia, however, was not surprised. “I think we made our point. I don’t think it’s seeping in well enough yet, but it will,” Monia told BioSpace on the sidelines of the J.P. Morgan Healthcare Conference in January. Kicking off a catalyst-rich year for Ionis, partner GSK on January 7 revealed that bepirovirsen achieved a “statistically significant and clinically meaningful functional cure rate” in a Phase 3 trial. GSK did not reveal the specific figures, only saying that the trial met its primary endpoint. The Big Pharma partner will release more details from the trial at the European Association for the Study of the Liver meeting this spring, while a new drug application will be filed in the first quarter. Monia explained that the trial measured a functional cure rate of about 15–20%, while existing treatments achieve maybe 1–3%. And last month’s bepirovirsen readout just scratches the surface of what Ionis has in store for 2026. Last year, the RNA interference biotech launched two products independently—Dawnzera for the prevention of hereditary angioedema attacks and Tryngolza for familial chylomicronemia syndrome (FCS). “Ionis has been historically an R&D organization. Now we built the commercial capabilities to support the launches that occurred,” Monia said. Cardiovascular disease Ionis’ Tryngolza ‘Game-Changing’ in Lowering Triglycerides, Cementing Case for FDA Filing Ionis is planning a supplemental submission by the end of the year to expand Tryngolza into severe hypertriglyceridemia. If granted, William Blair expects the antisense drug to be “transformational” for this indication. November 10, 2025 · 2 min read · Tristan Manalac Read More Tryngolza took home approximately $102 million in 2025 while Ionis has yet to report sales for Dawnzera. But the launch of the former has impressed analysts so far. William Blair in January predicted that Tryngolza could reach $2 billion in sales in 2034. Ionis also had two successful Phase 3 readouts last year, including one for Tryngolza in severe hypertriglyceridemia (sHTG). Monia said the data showed “remarkable reductions” in triglycerides. The trial, which could help support bringing the treatment into a larger disease population, helped underpin an FDA application at the end of the year. The initial launch success in FCS is “a sign of the company’s impressive salesforce in cardiometabolic disease and auspicious for a potential launch of Tryngolza in sHTG,” William Blair wrote in a January note. While Ionis has now launched medicines independently, the potential sHTG indication would be the first time the company has forayed into more common diseases. In this space, Ionis is up against Arrowhead Pharmaceuticals, another mid-sized biotech that is rising as an independent commercial company. Plozasiran was approved for FCS in November 2025 and a Phase 3 readout for sHTG is expected in the third quarter. With the FCS approval, Monia said Ionis priced the drug for a rare indication with a cost of $595,000. The CEO promised the price would come down as it moves into a more common indication. “Let’s face the facts: the FCS market—we pretty much created it, and we’re doing extremely well. There’s not much left for a competitor to come in,” Monia said. The specific sHTG price has not been announced, although William Blair put the wholesale acquisition cost between $10,000 to $20,000 per year—much lower than Arrowhead’s planned $60,000 cost for the rival medicine. Ionis also has zilganersen, which showed a disease-modifying benefit in a Phase 3 trial of patients with the rare neurodegenerative condition Alexander disease last year. Monia said that children with the devastating disorder typically do not survive past age four. Ionis plans to approval application for zilganersen this quarter. Elsewhere, Ionis’ partnered pipeline is advancing as well, with four Phase 3 readouts expected this year. In addition to GSK, the company has partnerships with AstraZeneca, Roche and Novartis, as well as a handful of smaller companies. “It seems like [2025] was the greatest year in our history, based on all of the achievements we made and how we transformed the company,” Monia said. “And I expect to make the same claim in December of this year.” Ionis will report earnings and provide company highlights on February 25. .responsive-container { display: flex; flex-wrap: wrap; border: 1px solid #ededed; font-family: Helvetica, Arial, Sans-Serif; padding: 20px 20px 10px 20px; } .column-left { flex: 1; max-width: 45%; padding: 20px 20px 10px 20px; } .column-right { flex: 2; padding: 20px 20px 10px 20px; } @media (max-width: 768px) { .column-left, .column-right { max-width: 100%; flex: 100%; padding: 10px 0; } } Subscribe to BioPharm Executive! Market insights, trending business and policy stories for biopharma leaders hbspt.forms.create({ region: "na1", portalId: "4413123", formId: "7c139b3c-ff0b-44e0-bffe-f449801dca59", onFormSubmitted: function($form, data) { window.dataLayer = window.dataLayer || []; window.dataLayer.push({ 'event': 'GTMevent', 'event_name': 'newsletter_sign_up' }); } });

Phase 3Clinical ResultAcquisitionDrug ApprovalOligonucleotide

10 Feb 2026

·www.prnewswire.com

Vanscoy Rare Pharmacy Selected as Exclusive Distribution Pharmacy for Redemplo® (plozasiran) for adults with Familial Chylomicronemia Syndrome (FCS)

PITTSBURGH, Feb. 10, 2026 /PRNewswire/ -- Vanscoy Rare Pharmacy, a leading specialty pharmacy focused on supporting people living with rare conditions, announced today that it has been selected as the exclusive specialty pharmacy provider for Redemplo® (plozasiran), a small interfering RNA (siRNA) medicine, indicated as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). FCS is a severe, rare disease, with an estimated 6,500 people in the U.S. living with genetic or clinical FCS, characterized by triglyceride levels that can be 10 to 100 times higher than normal leading to a substantially higher risk of developing acute, recurrent, and potentially fatal pancreatitis. With the FDA approval of Redemplo, patients will have access to a targeted treatment option designed to address the underlying cause of FCS. Through this agreement, Vanscoy Rare Pharmacy will provide patients with comprehensive support at each stage of their treatment journey with Redemplo. "We are honored to be selected as the exclusive Specialty Pharmacy dispensing Redemplo and to play a role in improving access for individuals and families affected by FCS," said Dr. Gordon Vanscoy, CEO, Vanscoy Rare Pharmacy. "Our team is deeply committed to ensuring that patients receive optimal support throughout their treatment journey — from initiation to long-term management." "Arrowhead Pharmaceuticals is proud to collaborate with Vanscoy Rare Pharmacy, whose experience in rare metabolic disorders and patient-centered approach align with our mission to treat diseases with significant unmet needs," said Chris Anzalone, CEO, Arrowhead Pharmaceuticals. INDICATION REDEMPLO® (plozasiran) is indicated as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS: None ADVERSE REACTIONS: Most common adverse reactions in REDEMPLO treated patients (incidence ≥10% of patient treated with REDEMPLO and >5% more frequently than with placebo) are hyperglycemia, headache, nausea, and injection site reaction. Prescribing Information Redemplohcp.com About Familial Chylomicronemia Syndrome (FCS) Familial chylomicronemia syndrome (FCS) is a severe and rare disease leading to extremely high triglyceride (TG) levels, typically over 880 mg/dl. Such severe elevations can lead to various signs and symptoms including acute and potentially fatal pancreatitis, chronic abdominal pain, diabetes, hepatic steatosis, and cognitive issues. Currently there are limited therapeutic options to adequately treat FCS. About Vanscoy Rare Pharmacy Vanscoy Rare Pharmacy is a triple accredited, national specialty pharmacy dedicated to providing high-touch care for patients with rare conditions. Through customized clinical programs, expert pharmacist support, and collaborative partnerships with manufacturers and providers, Vanscoy Rare Pharmacy ensures optimal access and outcomes for the patients it serves. Learn more at About Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing. For more information, visit SOURCE Vanscoy Rare Pharmacy 21% more press release views with Request a Demo

Drug ApprovalLicense out/in

27 Jan 2026

·www.businesswire.com

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-DIMER-PA, the company’s investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for atherosclerotic cardiovascular disease (ASCVD) due to mixed hyperlipidemia. ARO-DIMER-PA is designed to silence expression of both proprotein convertase subtilisin kexin 9 (PCSK9) and apolipoprotein C3 (APOC3) genes. This represents an important step forward for the field of RNAi therapeutics, as it is the first clinical candidate to target two genes simultaneously in one molecule, enabled by Arrowhead’s innovative and proprietary Targeted RNAi Molecule (TRiM™) platform. Arrowhead is at the forefront of innovation in the RNAi field, and we’re proud of the versatile capabilities of our TRiM platform, now including the first-ever clinical candidate that can potentially silence expression of two genes in one RNAi molecule Mixed hyperlipidemia is a highly prevalent disorder characterized by elevated levels of both low-density lipoprotein cholesterol (LDL-C) and triglycerides (TGs), and is a major risk factor for ASCVD, which is the leading cause of mortality worldwide and associated with substantial morbidity and healthcare costs. Despite the efficacy of LDL-C-lowering therapies in reducing ASCVD risk, there remains substantial residual risk in patients with mixed hyperlipidemia. “Arrowhead is at the forefront of innovation in the RNAi field, and we’re proud of the versatile capabilities of our TRiM™ platform, now including the first-ever clinical candidate that can potentially silence expression of two genes in one RNAi molecule,” said Chris Anzalone, Ph.D., President and CEO at Arrowhead Pharmaceuticals. “ARO-DIMER-PA is designed to silence both the PCSK9 and APOC3 genes, which together have substantial clinical validation as important targets for reducing LDL-cholesterol, triglycerides, and total atherogenic lipoproteins. We see ARO-DIMER-PA as having the potential to reduce the risk of ASCVD for people living with mixed hyperlipidemia, and we are excited to see what this study may reveal about the possibility of creating other dual-functional RNAi molecules for potentially treating complex genetic diseases.” The initiation of the clinical study for ARO-DIMER-PA is the latest advance in Arrowhead’s growing focus on RNAi therapeutics in the cardiometabolic therapeutic area – a portfolio that includes the company’s commercial product REDEMPLO® (plozasiran), now approved in the U.S., Canada, and China for the treatment of familial chylomicronemia syndrome (FCS), the ongoing Phase 3 study of zodasiran in homozygous familial hypercholesterolemia (HoFH), and ongoing Phase 1/2 studies of investigational ARO-INHBE and ARO-ALK7 being developed as potential treatments for obesity. Preclinical data on ARO-DIMER-PA were previously presented at the National Lipid Association (NLA) 2025 Annual Scientific Sessions and may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website. About ARO-DIMER-PA ARO-DIMER-PA is a dual-functional RNAi molecule designed to silence expression of both PCSK9 and APOC3 genes in hepatocytes. Prior clinical experience with other investigational and approved agents suggests that PCSK9 and APOC3 inhibition may lead to robust reductions in LDL-C, TGs, triglyceride rich lipoprotein remnants, and total atherogenic lipoproteins. ARO-DIMER-PA is the first clinical candidate designed to selectively silence the expression of two genes with a single RNAi molecule. About the ARO-DIMER-PA-1001 Phase 1/2a Study ARO-DIMER-PA-1001 (NCT07223658) is a Phase 1/2a placebo-controlled dose-escalating study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and effects on low-density lipoprotein cholesterol (LDL-C) and triglycerides (TGs) of single-dose ARO-DIMER-PA (part 1) and multiple doses of ARO-DIMER-PA (part 2) in up to 78 adult subjects with mixed hyperlipidemia. About Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. For more information, please visit www.arrowheadpharma.com, or follow us on X (formerly Twitter) at @ArrowheadPharma, LinkedIn, Facebook, and Instagram. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts. Safe Harbor Statement under the Private Securities Litigation Reform Act: This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “hope,” “intend,” “plan,” “project,” “could,” “estimate,” “continue,” “target,” “forecast” or “continue” or the negative of these words or other variations thereof or comparable terminology are intended to identify such forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our business, expectations for our product pipeline or product candidates, including anticipated regulatory submissions and clinical program results, prospects or benefits of our collaborations with other companies, or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements include, but are not limited to, statements about the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs; our expectations regarding the potential benefits of the partnership, licensing and/or collaboration arrangements and other strategic arrangements and transactions we have entered into or may enter into in the future; our beliefs and expectations regarding milestone, royalty or other payments that could be due to or from third parties under existing agreements; and our estimates regarding future revenues, research and development expenses, capital requirements and payments to third parties. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of numerous factors and uncertainties, including the safety and efficacy of our product candidates, decisions of regulatory authorities and the timing thereof, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, the enforcement of our intellectual property rights, and the other risks and uncertainties described in our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other documents filed with the Securities and Exchange Commission from time to time. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances. Source: Arrowhead Pharmaceuticals, Inc.

Drug ApprovalPhase 3

100 Deals associated with Plozasiran

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Familial chylomicronaemia syndrome	United States	Arrowhead Pharmaceuticals, Inc.	18 Nov 2025

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hypertriglyceridemia	NDA/BLA	Canada	Arrowhead Pharmaceuticals, Inc.	01 Jul 2025
Hyperlipoproteinemia Type I	Phase 3	United States	Arrowhead Pharmaceuticals, Inc.	14 Dec 2021
Hyperlipoproteinemia Type I	Phase 3	Japan	Arrowhead Pharmaceuticals, Inc.	14 Dec 2021
Hyperlipoproteinemia Type I	Phase 3	Argentina	Arrowhead Pharmaceuticals, Inc.	14 Dec 2021
Hyperlipoproteinemia Type I	Phase 3	Australia	Arrowhead Pharmaceuticals, Inc.	14 Dec 2021
Hyperlipoproteinemia Type I	Phase 3	Austria	Arrowhead Pharmaceuticals, Inc.	14 Dec 2021
Hyperlipoproteinemia Type I	Phase 3	Belgium	Arrowhead Pharmaceuticals, Inc.	14 Dec 2021
Hyperlipoproteinemia Type I	Phase 3	Canada	Arrowhead Pharmaceuticals, Inc.	14 Dec 2021
Hyperlipoproteinemia Type I	Phase 3	Croatia	Arrowhead Pharmaceuticals, Inc.	14 Dec 2021
Hyperlipoproteinemia Type I	Phase 3	France	Arrowhead Pharmaceuticals, Inc.	14 Dec 2021

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04998201 (MUIR, CTgov)	Phase 2	Dyslipidemias	353	Placebo (Placebo)	yfrytpisub(riogqlcckp) = bynpmyadvx nggcobrhnz (jgbutdrtvl, 3.07) View more	-	24 Feb 2026
				ARO-APOC3 (ARO-APOC3 10 mg Q12W)	yfrytpisub(riogqlcckp) = prmozhzclr nggcobrhnz (jgbutdrtvl, 3.54) View more
NCT05089084 (PALISADE, CTgov)	Phase 3	Hyperlipoproteinemia Type I	75	Plozasiran (ARO-APOC3 (Plozasiran) 25 mg)	umwwxvnhsy(fdzppqooms) = odnetpywac szyutpobbx (bvuomsqnfw, ccrjgmcybg - cdyrxtximi) View more	-	04 Feb 2026
				Plozasiran (ARO-APOC3 (Plozasiran) 50 mg)	umwwxvnhsy(fdzppqooms) = ewbmlsvlfi szyutpobbx (bvuomsqnfw, lrjwxrdvcs - jxkpkmhwcs) View more
NCT05089084 (FDA_CDER) Manual	Phase 3	Familial chylomicronaemia syndrome	51	REDEMPLO 25 mg	byfsdhlgow(atyyeusxax) = uglhrkaktq gxzstylcgv (wyiezxjthk ) View more	Positive	18 Nov 2025
				Placebo (pooled)	byfsdhlgow(atyyeusxax) = lzxacpufgn gxzstylcgv (wyiezxjthk ) View more
NCT05757596 (Pubmed \| Cardiovasc Diabetol) Manual	Phase 1	-	24	Plozasiran 25 mg	hvahyboake(umogfbcmjt) = eqrfdbkasd znaipcrmng (zomsvqqxjt ) View more	Positive	15 Oct 2025
				Plozasiran 50 mg	hvahyboake(umogfbcmjt) = nicyqmkjpt znaipcrmng (zomsvqqxjt ) View more
NCT05089084 (PALISADE, Corporate Publications \| ESC2025) Manual	Phase 3	Familial chylomicronaemia syndrome	-	Plozasiran (switched fr placebo)	lvlzylppvt(xqnghbuhyd) = trwonxuggn rhrlaaekfh (snqhebolqd ) View more	Positive	30 Aug 2025
				Plozasiran (continuous treated)	lvlzylppvt(xqnghbuhyd) = zxjpotqqeg rhrlaaekfh (snqhebolqd ) View more
NCT05902598 \| CTR20231418 (PRNewswire) Manual	Phase 3	Familial chylomicronaemia syndrome	37	VSA001 25 mg	infrcxwwtd(nvbukuugvd) = rhnkgsicql uzaoitgswh (tnxmjjxugg ) Met View more	Positive	17 Mar 2025
				VSA001 50 mg	infrcxwwtd(nvbukuugvd) = pbtmhrzsfh uzaoitgswh (tnxmjjxugg ) Met View more
NCT05089084 (PALISADE, Company_Website) Manual	Phase 3	Familial chylomicronaemia syndrome	75	Plozasiran 25 mg	ktfgifioaz(brfxjbyrrx) = jwyawnbjah dyatdtikms (nnwzaluedy ) View more	Positive	18 Nov 2024
				Plozasiran 50 mg	ktfgifioaz(brfxjbyrrx) = akjobpddvy dyatdtikms (nnwzaluedy ) View more
NCT04998201 \| NCT04720534 (MUIR, Company_Website) Manual	Phase 2	Hypertriglyceridemia \| Hyperlipidemia, Familial Combined	418	Plozasiran (MUIR)	ireynbnvwn(cibtfyfadx) = ndkbvgzctq xnlrehvgtd (ldueqcafuy )	Positive	18 Nov 2024
				Plozasiran (SHASTA-2)	ireynbnvwn(cibtfyfadx) = ovkcyvyxtn xnlrehvgtd (ldueqcafuy )
NCT05089084 (PALISADE, BusinessWire) Manual	Phase 3	Familial chylomicronaemia syndrome	75	PlozasiranPlozasiran 25 mg	npihskloqp(yrcajqwoke) = lomlmhjcsq ocyofxduoz (miqzrzjhmn ) View more	Positive	02 Sep 2024
				PlozasiranPlozasiran 50 mg	npihskloqp(yrcajqwoke) = krpnpvqnrh ocyofxduoz (miqzrzjhmn ) View more
NCT05089084 (PALISADE, Corporate Publications) Manual	Phase 3	Familial chylomicronaemia syndrome	75	Plozasiran 25 mg	psmgkqelgh(cldqcknawo) = tzzohthgxq qbgfonycwa (fvaaowhebd ) Met View more	Positive	03 Jun 2024
				Plozasiran 50 mg	psmgkqelgh(cldqcknawo) = ubflhqobvj qbgfonycwa (fvaaowhebd ) Met View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Plozasiran

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation